These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24138094)

  • 21. Exploring the Key Amino Acid Residues Surrounding the Active Center of Lactate Dehydrogenase A for the Development of Ideal Inhibitors.
    Chen J; Chen C; Zhang Z; Zeng F; Zhang S
    Molecules; 2024 Apr; 29(9):. PubMed ID: 38731521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.
    Dragovich PS; Fauber BP; Corson LB; Ding CZ; Eigenbrot C; Ge H; Giannetti AM; Hunsaker T; Labadie S; Liu Y; Malek S; Pan B; Peterson D; Pitts K; Purkey HE; Sideris S; Ultsch M; VanderPorten E; Wei B; Xu Q; Yen I; Yue Q; Zhang H; Zhang X
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3186-94. PubMed ID: 23628333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein flexibility in ligand docking and virtual screening to protein kinases.
    Cavasotto CN; Abagyan RA
    J Mol Biol; 2004 Mar; 337(1):209-25. PubMed ID: 15001363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-Dimensional Analysis of the Interactions between hLDH5 and Its Inhibitors.
    Poli G; Granchi C; Aissaoui M; Minutolo F; Tuccinardi T
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29236080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
    Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
    J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating ligand-based and protein-centric virtual screening of kinase inhibitors using ensembles of multiple protein kinase genes and conformations.
    Dixit A; Verkhivker GM
    J Chem Inf Model; 2012 Oct; 52(10):2501-15. PubMed ID: 22992037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient virtual screening using multiple protein conformations described as negative images of the ligand-binding site.
    Virtanen SI; Pentikäinen OT
    J Chem Inf Model; 2010 Jun; 50(6):1005-11. PubMed ID: 20504004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of receptor structural ensembles for virtual screening using binding site shape analysis and clustering.
    Osguthorpe DJ; Sherman W; Hagler AT
    Chem Biol Drug Des; 2012 Aug; 80(2):182-93. PubMed ID: 22515569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by Using a Pharmacophore-based Approach.
    Tuccinardi T; Poli G; Corchia I; Granchi C; Lapillo M; Macchia M; Minutolo F; Ortore G; Martinelli A
    Mol Inform; 2016 Sep; 35(8-9):434-9. PubMed ID: 27546047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deciphering ligand dependent degree of binding site closure and its implication in inhibitor design: A modeling study on human adenosine kinase.
    Bhutoria S; Ghoshal N
    J Mol Graph Model; 2010 Feb; 28(6):577-91. PubMed ID: 20089430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FlexE: efficient molecular docking considering protein structure variations.
    Claussen H; Buning C; Rarey M; Lengauer T
    J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BEAR, a novel virtual screening methodology for drug discovery.
    Degliesposti G; Portioli C; Parenti MD; Rastelli G
    J Biomol Screen; 2011 Jan; 16(1):129-33. PubMed ID: 21084717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase.
    D'Ursi P; Chiappori F; Merelli I; Cozzi P; Rovida E; Milanesi L
    Biochem Biophys Res Commun; 2009 Jun; 383(4):445-9. PubMed ID: 19371724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular dynamics in drug design.
    Zhao H; Caflisch A
    Eur J Med Chem; 2015 Feb; 91():4-14. PubMed ID: 25108504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring c-Met kinase flexibility by sampling and clustering its conformational space.
    Asses Y; Venkatraman V; Leroux V; Ritchie DW; Maigret B
    Proteins; 2012 Apr; 80(4):1227-38. PubMed ID: 22275094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
    Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
    J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation on the inhibition of pyrrol-2-yl ethanone derivatives to lactate dehydrogenase and anticancer activities.
    Lu NN; Weng ZY; Chen QY; Boison D; Xiao XX; Gao J
    Spectrochim Acta A Mol Biomol Spectrosc; 2016 Aug; 165():21-25. PubMed ID: 27104676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of novel human lactate dehydrogenase A inhibitors: High-throughput screening, synthesis, and biological evaluations.
    Zhou Y; Tao P; Wang M; Xu P; Lu W; Lei P; You Q
    Eur J Med Chem; 2019 Sep; 177():105-115. PubMed ID: 31129449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure of lactate dehydrogenase from Plasmodium vivax: complexes with NADH and APADH.
    Chaikuad A; Fairweather V; Conners R; Joseph-Horne T; Turgut-Balik D; Brady RL
    Biochemistry; 2005 Dec; 44(49):16221-8. PubMed ID: 16331982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.